Arrowhead Pharmaceuticals (ARWR) Financial Analysis & Valuation | Quarter Chart
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associat... more
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the ... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $7.90B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Christopher R. Anzalone |
| IPO Date | 1993-12-16 | CAGR | 39.35% |
| Employees | 711 | Website | arrowheadpharma.com |
| Div. Yield | — | Payout Ratio | -12% |
| Buy Back Yield | — | Total Yield | — |
ARWR chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $8.15B | P/E | -24.84 | Forward P/E | -11.23 | PEG | — |
| P/S | 0.01 | P/B | 0.01 | P/CF | -0.11 | P/FCF | -0.08 |
| Sales | $669.50M | Sales 1Y | 16.85% | Sales 3Y | 161.3% | Sales 5Y | 521.99% |
| EPS | $-2.25 | EPS 1Y | 72.31% | EPS 3Y | 30.99% | EPS 5Y | 83.61% |
| Sales QoQ | 2.06% | EPS QoQ | 46.24% | Sales QoQ Avg | 189.15% | EPS QoQ Avg | -198.1% |
| Gross Margin | 100% | Operating Margin | -33.82% | Profit Margin | -47.79% | ROCE | -12.38% |
| ROA | -15% | ROE | -61% | Altman Z Score | 2.49 | Piotroski Score | 3 |
| Current Ratio | 5.9 | Quick Ratio | 5.9 | Cash Ratio | 0.19 | Op. CF Ratio | -0.63 |
| Debt/Equity | 1.86 | Debt/Assets | 0.41 | Lt Debt/Equity | 1.77 | Lt Debt/Cap. | 0.64 |
| Intrst Cov. | -2.45 | Inventory Turnover | — | Asset Turnover | 0.32 | Receivables Turnover | 78.25 |
| Enterprise Value | $8.15B | P/E Ratio | -24.84 |
| Forward P/E | -11.23 | PEG Ratio | — |
| P/S Ratio | 0.01 | P/B Ratio | 0.01 |
| P/CF Ratio | -0.11 | P/FCF Ratio | -0.08 |
| EPS | $-2.25 | EPS Growth 1Y | 72.31% |
| EPS Growth 3Y | 30.99% | EPS Growth 5Y | 83.61% |
| Revenue Growth 1Y | 16.85% | Gross Margin | 100% |
| Operating Margin | -33.82% | Profit Margin | -47.79% |
| ROE | -61% | ROA | -15% |
| ROCE | -12.38% | Current Ratio | 5.9 |
| Quick Ratio | 5.9 | Cash Ratio | 0.19 |
| Debt/Equity | 1.86 | Interest Coverage | -2.45 |
| Altman Z Score | 2.49 | Piotroski Score | 3 |
Arrowhead Pharmaceuticals (ARWR) valuation & financials
Arrowhead Pharmaceuticals (ARWR) has a market capitalization of $7.90B and trades at a price-to-earnings ratio of -24.8. It operates in the Healthcare sector (Biotechnology).
Arrowhead Pharmaceuticals's revenue grew +16.8% over the last year.
Arrowhead Pharmaceuticals's next earnings report is scheduled for November 24, 2026 after market close (provider scheduled date); analysts estimate EPS of $-1.52. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)